Terms: = Lung cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Clinical Outcome
12 results:
1. Effective intravenous delivery of adenovirus armed with TNFα and il-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Kudling TV; Clubb JHA; Pakola S; Quixabeira DCA; Lähdeniemi IAK; Heiniö C; Arias V; Havunen R; Cervera-Carrascon V; Santos JM; Sutinen E; Räsänen J; Borenius K; Mäyränpää MI; Aaltonen E; Sorsa S; Hemminki O; Kanerva A; Verschuren EW; Ilonen I; Hemminki A
Oncoimmunology; 2023; 12(1):2241710. PubMed ID: 37546696
[TBL] [Abstract] [Full Text] [Related]
2. IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda cancer Institute.
Katongole P; Sande OJ; Nabweyambo S; Joloba M; Kajumbula H; Kalungi S; Reynolds SJ; Ssebambulidde K; Atuheirwe M; Orem J; Niyonzima N
Future Oncol; 2022 Feb; 18(6):661-667. PubMed ID: 34881637
[No Abstract] [Full Text] [Related]
3. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19.
Song J; Zeng M; Wang H; Qin C; Hou HY; Sun ZY; Xu SP; Wang GP; Guo CL; Deng YK; Wang ZC; Ma J; Pan L; Liao B; Du ZH; Feng QM; Liu Y; Xie JG; Liu Z
Allergy; 2021 Feb; 76(2):483-496. PubMed ID: 32716553
[TBL] [Abstract] [Full Text] [Related]
4. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures.
Carrega P; Loiacono F; Di Carlo E; Scaramuccia A; Mora M; Conte R; Benelli R; Spaggiari GM; Cantoni C; Campana S; Bonaccorsi I; Morandi B; Truini M; Mingari MC; Moretta L; Ferlazzo G
Nat Commun; 2015 Sep; 6():8280. PubMed ID: 26395069
[TBL] [Abstract] [Full Text] [Related]
5. Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study.
Hong CQ; Zhang F; You YJ; Qiu WL; Giuliano AE; Cui XJ; Zhang GJ; Cui YK
BMC Cancer; 2015 Jul; 15():548. PubMed ID: 26209438
[TBL] [Abstract] [Full Text] [Related]
6. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract] [Full Text] [Related]
7. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial.
Ridolfi L; Bertetto O; Santo A; Naglieri E; Lopez M; Recchia F; Lissoni P; Galliano M; Testore F; Porta C; Maglie M; Dall'agata M; Fumagalli L; Ridolfi R
Int J Oncol; 2011 Oct; 39(4):1011-7. PubMed ID: 21720704
[TBL] [Abstract] [Full Text] [Related]
8. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.
Recchia F; Saggio G; Nuzzo A; Biondi E; Di Blasio A; Cesta A; Candeloro G; Alesse E; Rea S
J Immunother; 2006; 29(1):87-94. PubMed ID: 16365604
[TBL] [Abstract] [Full Text] [Related]
9. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract] [Full Text] [Related]
10. Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel.
Isogai R; Kawada A; Aragane Y; Tezuka T
J Dermatol; 2004 Apr; 31(4):335-41. PubMed ID: 15187330
[TBL] [Abstract] [Full Text] [Related]
11. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G; Madeddu C; Gramignano G; Lusso MR; Mocci M; Massa E; Ferreli L; Astara G; Macciò A; Serpe R
J Exp Ther Oncol; 2003; 3(4):205-19. PubMed ID: 14567291
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
[TBL] [Abstract] [Full Text] [Related]
